N@N

IMRIS Receives Regulatory Approval In Japan

^{Published on 2009-05-26 09:53:59, Last Modified on 2009-05-26 09:54:36 - Market Wire}
 

 -- Asia-Pacific Expansion Continues -- WINNIPEG, May 26 /CNW/ - IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company") today announced that it has gained regulatory approval from the Ministry of Health in Japan for its intra-operative imaging system - IMRISneuro - and will immediately commence marketing from its office in Tokyo. Japan is recognized as the world's second largest market for high-end medical equipment after the United States and represents an important new opportunity for IMRIS. "Clearance in Japan is another milestone in our efforts to grow our customer base globally," said David Graves, CEO of IMRIS. "With projects in China, India and Australia, and with sales capabilities throughout the Asia-Pacific region, IMRIS is well placed to continue to increase its global market penetration." IMRISneuro has become the surgical imaging solution of choice by neurosurgeons around the world. The fully integrated surgical suite incorporates a one-of-a-kind technology that allows the surgical team to scan a patient with a high-field MRI during a procedure and obtain critical patient information without ever moving the patient. The result is more timely information enabling surgeons to make better decisions and improve patient outcomes. In addition to IMRISneuro, IMRIS is also pursuing regulatory approval in Japan and other regions for its recently introduced new product lines IMRISNV and IMRIScardio which have already received CE Mark approval for the European market. About IMRIS IMRIS (TSX: IM) is a global leader in providing fully integrated, advanced imaging solutions that serve the neurosurgical, cardiovascular and stroke management markets. The Company's flagship product IMRISneuro is in use by leading neurosurgeons at world-class neuroscience centers around the globe. For more information, visit [ www.imris.com ].

For further information: Media: Michael Robbie, Director, Marketing, Tel: (204) 480-7696, Email: [ mrobbie@imris.com ]; Investors: Brad Woods, Director, Investor Relations & Corporate Communications, Tel: (204) 480-7094, Email: [ bwoods@imris.com ]